Table 3.
Hazard ratios (HRs) and 95% confidence interval (CIs) comparing thromboembolic and bleeding complications in the first year after a vitamin K antagonist or non‐vitamin K antagonist oral anticoagulant prescription among AF patients with vs. without cancer by time since last cancer diagnosis and cancer type, Denmark, July 2004 through December 2013
| Thromboembolic complications | Bleeding complications | |
|---|---|---|
| HR (95% CI) | HR (95% CI) | |
| Time since cancer diagnosis | ||
| <2 years | 1.1 (0.99, 1.3) | 1.2 (1.0, 1.4) |
| 2 to <5 years | 0.92 (0.78, 1.1) | 1.1 (0.93, 1.3) |
| ≥5 years | 0.95 (0.85, 1.1) | 1.1 (0.95, 1.2) |
| Cancer site | ||
| Gastrointestinal cancer | 1.2 (0.94, 1.4) | 1.1 (0.85, 1.4) |
| Cancer of the lung or pleura | 1.5 (1.1, 2.2) | 2.0 (1.4, 2.8) |
| Breast cancer | 0.78 (0.61, 0.99) | 0.85 (0.63, 1.2) |
| Urological cancer | 1.0 (0.83, 1.3) | 1.7 (1.4, 2.0) |
| Intracranial cancer | 2.2 (0.31,16) | N/A |
| Hematological cancer | 0.65 (0.38, 1.1) | 0.61 (0.33, 1.1) |
| All other cancer sites | 0.99 (0.89, 1.1) | 1.0 (0.89, 1.2) |
Hazard ratios comparing patients with cancer to patients without cancer and adjusting for sex, age group, and CHA2DS2 VASc score.
N/A indicates no cases.